CareDx (CDNA) Trades 68% Above Fair Value Following Strong Q2 And Raised Guidance

CareDx (CDNA) has drawn fresh attention after reporting second quarter 2026 results, moving from a prior net loss to net income of $110.64 million, alongside higher year over year revenue and raised full year guidance.

See our latest analysis for CareDx.

The latest earnings announcement and raised 2026 guidance have come alongside a sharp shift in sentiment toward CareDx, with a 30 day share price return of 65.10% and a year to date share price return of 145.92%. Over a longer horizon, the 1 year total shareholder return of 299.92% and 3 year total shareholder return of 403.69% contrast with a 5 year total shareholder return that is still down 33.94%, which suggests momentum has recently strengthened from a previously weaker period.

If strong earnings turnarounds catch your attention, this can be a good moment to broaden your watchlist and see what stands out in the 43 healthcare AI stocks

CareDx now appears to be a much stronger business based on recent earnings results, yet the share price has already moved a long way. The next step is to ask whether that recent strength is already fully reflected in today’s valuation.

Most Popular Narrative: 68.1% Overvalued

CareDx last closed at $47.07, while the most followed narrative pegs fair value at $28.00. That gap is driving a very different take on today’s price.

The assumed bullish price target for CareDx is $28.0, which represents up to two standard deviations above the consensus price target of $25.8. This valuation is based on what can be assumed as the expectations of CareDx's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.

Read the complete narrative.

Want to see what has to happen for CareDx to live up to that $28.00 fair value? The narrative leans heavily on faster revenue expansion, much higher margins, and a richer earnings multiple than the wider biotech group. The exact mix of those three levers is where the story gets interesting.

Result: Fair Value of $28 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, even bullish CareDx narratives flag real pressure points, including potential Medicare reimbursement changes and greater pricing power for large transplant centers that could squeeze margins.

Find out about the key risks to this CareDx narrative.

Another View on CareDx Using Earnings Multiples

The fair value narrative for CareDx points to $28.00 as a reference price, which puts today’s $47.07 share price well above that mark. Yet on a P/E basis, CareDx trades on 21.9x earnings, which is lower than the peer average of 36.2x but higher than the US Biotechs industry average of 17.2x. The estimated fair ratio is 5.9x, so if the market moved closer to that level it would imply a lot more downside than the narrative suggests. Which yardstick do you place more weight on when numbers send mixed signals?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals around CareDx valuation and sentiment, this is a good time to review the full picture for yourself and act promptly. To see both sides laid out in one place, start with the 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond CareDx?

If CareDx is already on your radar, do not stop there. Broaden your research now or you may miss opportunities that better match your goals.

• Spot opportunities in financially healthy companies by scanning the solid balance sheet and fundamentals stocks screener (48 results) that can handle tougher conditions without stretching their balance sheets.
• Zero in on potential bargains by reviewing the 52 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their strengths.
• Focus on resilience by checking the 83 resilient stocks with low risk scores which highlights stocks with lower risk scores for investors who prioritize capital preservation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com